Business Summary

Race Oncology Limited is an Australia-based precision oncology company. The Company is engaged in the research of the oncology drug, Zantrene and the manufacturing and distribution of the drug for the clinical trials. Zantrene is a potent small molecule inhibitor of the fatso/fat mass and obesity-associated (FTO) protein. Zantrene is in the Phase II/III trials. The Company is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma (kidney cancer), which are both frequent FTO-driven cancers. The Company also has clinical data for the use of Zantrene as a chemotherapeutic agent with reduced cardiotoxicity in acute myeloid leukemia (AML), breast and ovarian cancers and is investigating its use in these areas.